Literature DB >> 15312137

Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour.

Ian Todd1, Paul M Radford, Kelly-Ann Draper-Morgan, Richard McIntosh, Susan Bainbridge, Peter Dickinson, Lama Jamhawi, Marios Sansaridis, Mary L Huggins, Patrick J Tighe, Richard J Powell.   

Abstract

Tumour necrosis factor (TNF)-receptor-associated periodic syndrome (TRAPS) is a hereditary autoinflammatory disorder involving autosomal-dominant missense mutations in TNF receptor superfamily 1A (TNFRSF1A) ectodomains. To elucidate the molecular effects of TRAPS-related mutations, we transfected HEK-293 cells to produce lines stably expressing high levels of either wild-type (WT) or single mutant recombinant forms of TNFRSF1A. Mutants with single amino acid substitutions in the first cysteine-rich domain (CRD1) were produced both as full-length receptor proteins and as truncated forms lacking the cytoplasmic signalling domain (deltasig). High-level expression of either WT or mutant full-length TNFRSF1A spontaneously induced apoptosis and interleukin-8 production, indicating that the mutations in CRD1 did not abrogate signalling. Consistent with this, WT and mutant full-length TNFRSF1A formed cytoplasmic aggregates that co-localized with ubiquitin and chaperones, and with the signal transducer TRADD, but not with the inhibitor, silencer of death domain (SODD). Furthermore, as expected, WT and mutant deltasig forms of TNFRSF1A did not induce apoptosis or interleukin-8 production. However, whereas the WT full-length TNFRSF1A was expressed both in the cytoplasm and on the cell surface, the mutant receptors showed strong cytoplasmic expression but reduced cell-surface expression. The WT and mutant deltasig forms of TNFRSF1A were all expressed at the cell surface, but a proportion of the mutant receptors were also retained in the cytoplasm and co-localized with BiP. Furthermore, the mutant forms of surface-expressed deltasig TNFRSF1A were defective in binding TNF-alpha. We conclude that TRAPS-related CRD1 mutants of TNFRSF1A possess signalling properties associated with the cytoplasmic death domain, but other behavioural features of the mutant receptors are abnormal, including intracellular trafficking and TNF binding.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15312137      PMCID: PMC1782552          DOI: 10.1111/j.1365-2567.2004.01942.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  46 in total

1.  Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes.

Authors:  M F McDermott; I Aksentijevich; J Galon; E M McDermott; B W Ogunkolade; M Centola; E Mansfield; M Gadina; L Karenko; T Pettersson; J McCarthy; D M Frucht; M Aringer; Y Torosyan; A M Teppo; M Wilson; H M Karaarslan; Y Wan; I Todd; G Wood; R Schlimgen; T R Kumarajeewa; S M Cooper; J P Vella; C I Amos; J Mulley; K A Quane; M G Molloy; A Ranki; R J Powell; G A Hitman; J J O'Shea; D L Kastner
Journal:  Cell       Date:  1999-04-02       Impact factor: 41.582

Review 2.  The tumor necrosis factor ligand and receptor families.

Authors:  F Bazzoni; B Beutler
Journal:  N Engl J Med       Date:  1996-06-27       Impact factor: 91.245

3.  TNF recruits TRADD to the plasma membrane but not the trans-Golgi network, the principal subcellular location of TNF-R1.

Authors:  S J Jones; E C Ledgerwood; J B Prins; J Galbraith; D R Johnson; J S Pober; J R Bradley
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

4.  Calpain activation is upstream of caspases in radiation-induced apoptosis.

Authors:  N J Waterhouse; D M Finucane; D R Green; J S Elce; S Kumar; E S Alnemri; G Litwack; K Khanna; M F Lavin; D J Watters
Journal:  Cell Death Differ       Date:  1998-12       Impact factor: 15.828

5.  TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation.

Authors:  J J Peschon; D S Torrance; K L Stocking; M B Glaccum; C Otten; C R Willis; K Charrier; P J Morrissey; C B Ware; K M Mohler
Journal:  J Immunol       Date:  1998-01-15       Impact factor: 5.422

6.  Clinical spectrum of familial Hibernian fever: a 14-year follow-up study of the index case and extended family.

Authors:  E M McDermott; D M Smillie; R J Powell
Journal:  Mayo Clin Proc       Date:  1997-09       Impact factor: 7.616

7.  Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks.

Authors:  Catherine Dodé; Bouke P C Hazenberg; Christophe Pêcheux; Daniel Cattan; Bruno Moulin; Anne Barthélémy; Marie-Claire Gubler; Marc Delpech; Gilles Grateau
Journal:  Nephrol Dial Transplant       Date:  2002-07       Impact factor: 5.992

8.  Disparate localization of 55-kd and 75-kd tumor necrosis factor receptors in human endothelial cells.

Authors:  J R Bradley; S Thiru; J S Pober
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

9.  Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection.

Authors:  K Pfeffer; T Matsuyama; T M Kündig; A Wakeham; K Kishihara; A Shahinian; K Wiegmann; P S Ohashi; M Krönke; T W Mak
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

10.  Aggresomes: a cellular response to misfolded proteins.

Authors:  J A Johnston; C L Ward; R R Kopito
Journal:  J Cell Biol       Date:  1998-12-28       Impact factor: 10.539

View more
  24 in total

1.  Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome.

Authors:  Anna Simon; Heiyoung Park; Ravikanth Maddipati; Adrian A Lobito; Ariel C Bulua; Adrianna J Jackson; Jae Jin Chae; Rachel Ettinger; Heleen D de Koning; Anthony C Cruz; Daniel L Kastner; Hirsh Komarow; Richard M Siegel
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

2.  A novel TNFRSF1 gene mutation in a Turkish family: a report of three cases.

Authors:  Fulya Cosan; Ayten Yazici; Barış Yılmazer; Ahmet Gul; Duran Ustek; Ayse Cefle
Journal:  Clin Rheumatol       Date:  2010-06-10       Impact factor: 2.980

3.  Functional analysis of a novel G87V TNFRSF1A mutation in patients with TNF receptor-associated periodic syndrome.

Authors:  S Tsuji; H Matsuzaki; M Iseki; A Nagasu; H Hirano; K Ishihara; N Ueda; Y Honda; T Horiuchi; R Nishikomori; Y Morita; T Mukai
Journal:  Clin Exp Immunol       Date:  2019-09-04       Impact factor: 4.330

4.  Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus.

Authors:  Linda Ottoboni; Irene Y Frohlich; Michelle Lee; Brian C Healy; Brendan T Keenan; Zongqi Xia; Tanuja Chitnis; Charles R Guttmann; Samia J Khoury; Howard L Weiner; David A Hafler; Philip L De Jager
Journal:  Neurology       Date:  2013-10-30       Impact factor: 9.910

5.  The association of TNFRSF1A gene and MEFV gene mutations with adult onset Still's disease.

Authors:  Fulya Cosan; Zeliha Emrence; Gokhan Erbag; Hulya Azakli; Baris Yilmazer; Ayten Yazici; Sema Sirma Ekmekci; Neslihan Abaci; Duran Ustek; Ayse Cefle
Journal:  Rheumatol Int       Date:  2012-12-27       Impact factor: 2.631

6.  Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS).

Authors:  Adrian A Lobito; Fiona C Kimberley; Jagan R Muppidi; Hirsh Komarow; Adrianna J Jackson; Keith M Hull; Daniel L Kastner; Gavin R Screaton; Richard M Siegel
Journal:  Blood       Date:  2006-05-09       Impact factor: 22.113

Review 7.  Protein misfolding and dysregulated protein homeostasis in autoinflammatory diseases and beyond.

Authors:  Amma F Agyemang; Stephanie R Harrison; Richard M Siegel; Michael F McDermott
Journal:  Semin Immunopathol       Date:  2015-05-21       Impact factor: 9.623

Review 8.  Tumor necrosis factor-associated periodic syndrome in adults.

Authors:  Sharika Gopakumar Menon; Petros Efthimiou
Journal:  Rheumatol Int       Date:  2017-09-23       Impact factor: 2.631

9.  Silencer of death domains (SODD) inhibits skeletal muscle and kidney enriched inositol 5-phosphatase (SKIP) and regulates phosphoinositide 3-kinase (PI3K)/Akt signaling to the actin cytoskeleton.

Authors:  Parvin Rahman; Richard D Huysmans; Fenny Wiradjaja; Rajendra Gurung; Lisa M Ooms; David A Sheffield; Jennifer M Dyson; Meredith J Layton; Absorn Sriratana; Hidetoshi Takada; Tony Tiganis; Christina A Mitchell
Journal:  J Biol Chem       Date:  2011-06-28       Impact factor: 5.157

10.  Alix and ALG-2 are involved in tumor necrosis factor receptor 1-induced cell death.

Authors:  Anne-Laure Mahul-Mellier; Flavie Strappazzon; Anne Petiot; Christine Chatellard-Causse; Sakina Torch; Béatrice Blot; Kimberley Freeman; Loriane Kuhn; Jérome Garin; Jean-Marc Verna; Sandrine Fraboulet; Rémy Sadoul
Journal:  J Biol Chem       Date:  2008-10-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.